Structure via PubChem · Public domain (PubChem)
tamibarotene
Sign in to saveAlso known as AM-80, AM80, Amnolake®, retinobenzoic acid, Am 80, Amnolake
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) . It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. Tamibarotene has been tested in many other cancer types, including Acute Myeloid Leukemia where it shows no benefit, and lung cancer, where it accelerated the cancer growth and increased mortality.
In the Vinony graph
Within Vinony's link graph, tamibarotene is referenced by 36 other articles, and connects out to tiazofurin, medication and Alzheimer's disease.
It is catalogued under topics including Antineoplastic drugs, Benzoic acids and Retinoids.
Its subject is documented across 7 Wikipedia language editions.
Chemical data
- Formula
- C22H25NO3
- Molecular weight
- 351.4 g/mol
- IUPAC name
- 4-[(5,5,8,8-tetramethyl-6,7-dihydronaphthalen-2-yl)carbamoyl]benzoic acid
- SMILES
- CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
- InChIKey
- MUTNCGKQJGXKEM-UHFFFAOYSA-N
- XLogP
- 5.4
- Polar surface area
- 66.4 Ų
- H-bond donors
- 2
- H-bond acceptors
- 3
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- Admin. routes
- oral
- Indications
- Crohn's disease, myelodysplastic syndrome, acute myeloid leukemia, acute promyelocytic leukemia
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 351.183
- Has use
- medication
Show 3 more facts
- chemical formula
- C₂₂H₂₅NO₃
- canonical SMILES
- CC1(CCC(C2=C1C=CC(=C2)NC(=O)C3=CC=C(C=C3)C(=O)O)(C)C)C
- Commons category
- Tamibarotene
Sources (2)
via Wikidata · CC0
~1 min read
Encyclopedic overview
2 sectionsContents
- Synthesis
- References
Tamibarotene (brand name: Amnolake), also called retinobenzoic acid, is orally active, synthetic retinoid, developed to overcome all-trans retinoic acid (ATRA) resistance, with potential antineoplastic activity against acute promyelocytic leukaemia (APL) . It is currently marketed only in Japan and early trials have demonstrated that it tends to be better tolerated than ATRA. Tamibarotene has been tested in many other cancer types, including Acute Myeloid Leukemia where it shows no benefit, and lung cancer, where it accelerated the cancer growth and increased mortality.
It has also been investigated as a possible treatment for Alzheimer's disease, multiple myeloma and Crohn's disease. Tamibarotene shows a similar side effect profile to Tretinoin, but exhibits lower clearance, resulting in improved dosing regiments. Hyperlipidemia is a common finding from Tamibarotene dosing.
Excerpted from Wikipedia’s “tamibarotene” article, available under the CC BY-SA 4.0 licence.